Abiraterone
- Generic Name
- Abiraterone
- Brand Names
- Yonsa, Zytiga, Abiraterone Krka, Abiraterone Accord, Abiraterone Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C24H31NO
- CAS Number
- 154229-19-3
- Unique Ingredient Identifier
- G819A456D0
- Background
Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis. Abiraterone was first approved by the FDA and EMA on April, July, and September 2011, respectively. It is used to treat metastatic castration-resis...
- Indication
Abiraterone is indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in combination with methylprednisolone or prednisone.
...
- Associated Conditions
- Metastatic Castration Sensitive Prostate Cancer (mCSPC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
- Associated Therapies
- -
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-11-18
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Amgen
- Target Recruit Count
- 675
- Registration Number
- NCT06691984
- Locations
- 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial
- Conditions
- Interventions
- First Posted Date
- 2024-10-21
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Emory University
- Target Recruit Count
- 72
- Registration Number
- NCT06650579
- Locations
- 🇺🇸
Emory Proton Therapy Center, Atlanta, Georgia, United States
🇺🇸Winship at Emory Midtown, Atlanta, Georgia, United States
🇺🇸Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
- Conditions
- Interventions
- Other: Genetic testingDrug: Valemetostat TosylateProcedure: Magnetic Resonance ImagingProcedure: Computed TomographyProcedure: Bone scanProcedure: FDG-Positron Emission TomographyProcedure: PSMA PET ScanProcedure: Biospecimen CollectionDrug: CarboplatinDrug: CabazitaxelDrug: Abiraterone AcetateDrug: EnzalutamideDrug: Lutetium Lu 177 Vipivotide Tetraxetan
- First Posted Date
- 2024-10-09
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 474
- Registration Number
- NCT06632977
Phase II Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-09-27
- Last Posted Date
- 2024-12-11
- Target Recruit Count
- 58
- Registration Number
- NCT06616597
- Locations
- 🇺🇸
Sibley Memorial Hospital, Washington, District of Columbia, United States
🇺🇸Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Docetaxel and Hormone Treatment Compared to Hormone Treatment Alone in People With Metastatic Castration Sensitive Prostate Cancer and Less Than Optimal PSA Response
- Conditions
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Canadian Cancer Trials Group
- Target Recruit Count
- 830
- Registration Number
- NCT06592924
The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT GLOBAL)
- Conditions
- Interventions
- First Posted Date
- 2024-07-25
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
- Target Recruit Count
- 430
- Registration Number
- NCT06520345
- Locations
- 🇺🇸
Biogenix Molecular LLC, Miami, Florida, United States
🇺🇸XCancer Omaha, Omaha, Nebraska, United States
🇦🇺Westmead Hospital, Sydney, New South Wales, Australia
A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-06-13
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT06457919
- Locations
- 🇺🇸
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
Outcomes of Local Treatment for Oligometastatic Prostate Cancer Diagnosed Using PSMA PET Imaging: OLIGOMET Study
- First Posted Date
- 2024-05-28
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 500
- Registration Number
- NCT06430411
M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)
- Conditions
- Interventions
- First Posted Date
- 2024-05-20
- Last Posted Date
- 2024-12-19
- Target Recruit Count
- 96
- Registration Number
- NCT06421935
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
🇰🇷Severance Hospital, Yonsei University Health System - Division of Infectious Diseases, Seoul, Korea, Republic of
🇪🇸Hospital Universitari Vall d'Hebron - Oncology Dept., Barcelona, Spain
Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations
- Conditions
- Interventions
- First Posted Date
- 2024-04-30
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- Qian Qin
- Target Recruit Count
- 64
- Registration Number
- NCT06392841
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.